IP Library Granted Patent US 7,963,935
Granted Patent B2
US 7,963,935 · App. 10/127,108 · Granted Jun 21, 2011

Microprojection array having a beneficial agent containing coating

Assignee: Alza Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,963,935
App. No.
10/127,108
Granted
Jun 21, 2011
Kind
B2
Abstract

The device including a plurality of stratum corneum-piercing microprojections, and a solid coating disposed upon the microprojections, wherein the solid coating includes at least one beneficial agent and a biocompatible carrier is provided. The device is applied to the skin of a living animal (e.g., a human), causing the microprojections to pierce the stratum corneum and deliver an effective dose of the agent to the animal.

Claims (28)

1. A device for delivering a beneficial agent through the stratum corneum, the device comprising:

a plurality of stratum corneum-piercing microprojections;

a coating disposed as a homogenous, amorphous glassy form upon at least a portion of said microprojections,

wherein the coating is substantially dried and includes at least one beneficial agent and at least one water soluble biocompatible carrier;

wherein said agent is dissolved or suspended in said carrier,

wherein said coating is placed in contact with body fluid after the microprojections have pierced the stratum corneum, and wherein said at least one water soluble biocompatible carrier comprises human albumin.

2. The device of claim 1 , wherein said human albumin is bio-engineered human albumin.

3. The device of claim 1 , wherein the at least one beneficial agent is suspended in the at least one water soluble biocompatible carrier.

4. The device of claim 1 , wherein the at least one beneficial agent is selected from the group consisting of vaccines and desensitizing agents.

5. The device of claim 1 , wherein the ratio of all biocompatible carriers to all beneficial agents range from about 0.2:1 to about 5:1 weight/weight.

6. The device of claim 1 , wherein the ratio of all biocompatible carriers to all beneficial agents range from about 0.5:1 to about 2:1 weight/weight.

7. The device of claim 1 , wherein the coating includes a plurality of beneficial agents.

8. The device of claim 1 , wherein each of the at least one beneficial agents are included on coatings which are on separate portions of the plurality of microprojections.

9. The device of claim 1 , wherein the at least one biocompatible carrier further includes at least one carrier selected from the group consisting of sucrose, trehalose, melezitose, raffinose, and stachyose.

10. A device for delivering a beneficial agent through the stratum corneum, the device comprising:

a plurality of stratum corneum-piercing microprojections;

a coating disposed as a homogeneous, amorphous glassy form upon at least a portion of said microprojections;

wherein the coating is substantially dried and includes at least one beneficial agent and at least one water soluble biocompatible carrier;

wherein said agent is dissolved or suspended in said carrier,

wherein said coating is placed in contact with body fluid after the microprojections have pierced the stratum corneum, and

wherein the at least one water soluble biocompatible carrier is selected from the group consisting of dextran sulfate, pentosan polysulfate, polyglutamic acid, polyaspartic acid, polyhistidine, and non-reducing sugars.

11. A device for delivering a beneficial agent through the stratum corneum, the device comprising:

a plurality of stratum corneum-piercing microprojections;

a coating disposed as a homogeneous, amorphous glassy form upon at least a portion of said microprojections;

wherein the coating is substantially dried and includes at least one beneficial agent and at least one water soluble biocompatible carrier;

wherein said agent is dissolved or suspended in said carrier,

wherein said coating is placed in contact with body fluid after the microprojections have pierced the stratum corneum, and

wherein the at least one water soluble biocompatible carrier is a polyamino acid.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 31, 2022
From: HERCULES CAPITAL, INC.
To: ZOSANO PHARMA CORPORATION
Reel/Frame 059559/0723 →
SECURITY INTEREST Recorded Jun 19, 2014
From: ZOSANO PHARMA, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 033203/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2003
From: CORMIER, MICHAEL J. N.; YOUNG, WENDY A.; JOHNSON, JUANITA A.; DADDONA, PETER E.
To: ALZA CORPORATION
Reel/Frame 014175/0925 →
Continuity (2)
Provisional Application 60285576 · Apr 20, 2001
Related Publication 20020177839A1 · Nov 28, 2002